Cibus Crecimiento futuro
Future controles de criterios 2/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Cibus de 49.3% y 50.8% respectivamente, mientras que el BPA crecerá en un 57.9% al año.
Información clave
49.3%
Tasa de crecimiento de los beneficios
57.95%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 25.3% |
| Tasa de crecimiento de los ingresos | 50.8% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 13 May 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
CBUS: Higher Future P/E And Raised Discount Rate Will Shape Rerating Potential
Analysts have raised their price target on Cibus by $1.10. They cite updated assumptions around discount rate, revenue growth and profit margin as key reasons for the change.CBUS: Higher Future P/E Expectations Will Drive Rerated Upside Potential
Narrative Update on Cibus The analyst price target for Cibus has been raised by $1.10. Analysts point to an updated fair value estimate of $3.00, a higher discount rate, adjusted revenue growth and profit margin assumptions, and a much higher future P/E outlook as key drivers of the change.CBUS: Premium Price And Dilutive Equity Raise Will Limit Future Upside
Analysts have revised their price target on Cibus to $1.90, reflecting updated assumptions for discount rate, revenue growth, profit margin and future P/E, while keeping fair value steady at $1.90 as they balance growth expectations with valuation similar to recent Neutral views seen in Community Financial research. Analyst Commentary Recent street research on other financial names shows a pattern of cautious stances where valuation and growth expectations are tightly linked.CBUS: Premium Share Price And Equity Issuance Will Restrain Future Returns
The analyst price target for Cibus has been revised to $65 from $72 as analysts recalibrate expected profit margins and apply a higher assumed future P/E multiple, while keeping their fair value estimate broadly unchanged and highlighting valuation as the key constraint on further upside. Analyst Commentary Recent Street research on Cibus highlights a cautious tone, with several bearish analysts pointing to valuation as the main sticking point.CBUS: Equity Offering And Execution Demands Will Constrain Future Share Returns
Analysts have adjusted their price target on Cibus to $1.90, reflecting updated assumptions around the discount rate, long term revenue growth, and future P/E, while keeping their fair value view unchanged at $1.90. Analyst Commentary Bearish analysts are signaling a more cautious stance on Cibus, even as the fair value view sits at $1.90.CBUS: Reset Fair Value And Equity Raise Will Restrain Long Term Upside
Analysts have reset their fair value estimate for Cibus to $1.90 from $15.00, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E expectations. Analyst Commentary Bearish analysts have reset their expectations for Cibus, and the sharp cut in the fair value estimate to US$1.90 signals a more cautious stance on the stock.CBUS: Latin American Rice Trait Partnership Will Shape Long Term Upside
Narrative update Analysts have raised their fair value estimate for Cibus from US$1.60 to US$15.00, citing updated assumptions for revenue growth, profit margins and future P/E expectations as key drivers of the change. Analyst Commentary While the updated fair value estimate for Cibus now stands at US$15.00, some readers may find it useful to consider how bearish analysts have approached similar valuation resets in other names.
Licensing And EU Harmonization Will Open New Markets
Following sharp reductions in both Cibus’s future P/E ratio and discount rate, reflecting improved earnings outlook and lower perceived risk, the consensus analyst price target has dropped from $16.38 to $14.40. What's in the News Cibus was dropped from multiple Russell indices, including the Russell 2000, 2500, 3000, Small Cap Completeness Index, and their respective value subsets.
Licensing And EU Harmonization Will Open New Markets
Transitioning to a commercial trait company and leveraging licensing agreements can unlock new revenue streams and enhance market penetration.Cibus: Expanding Opportunities And Growing Accessible Market
Summary Cibus, a gene editing pioneer in agriculture, has announced collaborations that could significantly increase its revenues. The company has partnered with Interoc to breed rice hybrids with herbicide tolerance for the Latin American market. Further deals in Latin America could double or triple accessible rice acreage. Cibus has also achieved a breakthrough in regenerating wheat plants from single cells, opening up a large addressable market for enhanced forms of wheat. Read the full article on Seeking AlphaPrevisiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 42 | -62 | -65 | -61 | 2 |
| 12/31/2027 | 14 | -68 | -60 | -32 | 4 |
| 12/31/2026 | 8 | -70 | -60 | -38 | 4 |
| 12/31/2025 | 4 | -127 | -51 | -51 | N/A |
| 9/30/2025 | 4 | -119 | -52 | -51 | N/A |
| 6/30/2025 | 5 | -275 | -54 | -53 | N/A |
| 3/31/2025 | 5 | -275 | -57 | -56 | N/A |
| 12/31/2024 | 4 | -251 | -59 | -58 | N/A |
| 9/30/2024 | 4 | -445 | -62 | -61 | N/A |
| 6/30/2024 | 3 | -292 | -67 | -63 | N/A |
| 3/31/2024 | 2 | -286 | -62 | -57 | N/A |
| 12/31/2023 | 2 | -268 | -51 | -46 | N/A |
| 9/30/2023 | 1 | -53 | -37 | -33 | N/A |
| 6/30/2023 | 0 | -33 | -23 | -22 | N/A |
| 3/31/2023 | 0 | -17 | -16 | -15 | N/A |
| 12/31/2022 | 0 | -17 | -21 | -19 | N/A |
| 9/30/2022 | 2 | -21 | -21 | -20 | N/A |
| 6/30/2022 | 10 | -22 | -20 | -19 | N/A |
| 3/31/2022 | 22 | -25 | -17 | -16 | N/A |
| 12/31/2021 | 26 | -29 | -19 | -19 | N/A |
| 9/30/2021 | 38 | -36 | -28 | -27 | N/A |
| 6/30/2021 | 35 | -38 | -31 | -29 | N/A |
| 3/31/2021 | 26 | -44 | -43 | -41 | N/A |
| 12/31/2020 | 24 | -45 | -45 | -44 | N/A |
| 9/30/2020 | 14 | -44 | -40 | -38 | N/A |
| 6/30/2020 | 11 | -45 | -44 | -42 | N/A |
| 3/31/2020 | 10 | -43 | -38 | -35 | N/A |
| 12/31/2019 | 7 | -40 | -35 | -32 | N/A |
| 9/30/2019 | 4 | -36 | N/A | -31 | N/A |
| 6/30/2019 | 1 | -33 | N/A | -27 | N/A |
| 3/31/2019 | 0 | -31 | N/A | -23 | N/A |
| 12/31/2018 | 0 | -28 | N/A | -20 | N/A |
| 9/30/2018 | 0 | -26 | N/A | -20 | N/A |
| 6/30/2018 | 0 | -32 | N/A | -18 | N/A |
| 3/31/2018 | 0 | -28 | N/A | -18 | N/A |
| 12/31/2017 | 1 | -26 | N/A | -13 | N/A |
| 9/30/2017 | 0 | -24 | N/A | -9 | N/A |
| 6/30/2017 | 0 | -13 | N/A | -11 | N/A |
| 3/31/2017 | 0 | -12 | N/A | -9 | N/A |
| 12/31/2016 | 0 | -12 | N/A | -9 | N/A |
| 12/31/2015 | 1 | -6 | N/A | -7 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que CBUS siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que CBUS siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que CBUS siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (50.8% al año) de CBUS crezcan más rápidamente que los del mercado US (11.6% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (50.8% al año) de CBUS crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de CBUS se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/13 12:57 |
| Precio de las acciones al final del día | 2026/05/13 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Cibus, Inc. está cubierta por 13 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Matthew Venezia | Alliance Global Partners |
| Donald McLee | Berenberg |
| Kenneth Zaslow | BMO Capital Markets Equity Research |